title: Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
authors.affiliation: St. Luke's Mountain States Tumor Institute, Boise, Idaho, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Mancini
authors.forename: Ali
authors.initials: A
authors.lastname: McBride
authors.forename: Mary
authors.initials: M
authors.lastname: Kruczynski
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000191:economics*; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D018166:Health Care Reform / Q000191:economics / Q000331:legislation & jurisprudence; D006291:Health Policy / Q000191:economics* / Q000331:legislation & jurisprudence; D006297:Health Services Accessibility / Q000191:economics* / Q000331:legislation & jurisprudence; D054625:Healthcare Disparities / Q000191:economics* / Q000331:legislation & jurisprudence; D006801:Humans; D019458:Insurance Coverage / Q000191:economics / Q000331:legislation & jurisprudence; D007348:Insurance, Health / Q000191:economics / Q000331:legislation & jurisprudence; D058991:Patient Protection and Affordable Care Act / Q000191:economics / Q000331:legislation & jurisprudence; D016896:Treatment Outcome; D014481:United States
chemical_list: D000970:Antineoplastic Agents